Vanta Bioscience Ltd
VANTABIOBSE
₹20.40▲ +0.00 (+0.00%)
Whole company worth₹15 Cr
Price for ₹1 of profit₹136
1-year range₹15 – ₹26
The short version
A shrinking, thinly profitable business — priced richly for what it earns.
What Vanta Bioscience does
Incorporated in 2016, Vanta Bioscience Ltd is a full-service preclinical contract research organisation.
Worked out from Vanta Bioscience's own filed results and exchange data, in plain words. Where a finance term matters, we say what it means.
01What does it do?
Vanta Bioscience is a micro-sized company in healthcare technology.
Incorporated in 2016, Vanta Bioscience Ltd is a full-service preclinical contract research organisation.
- Whole company is worth
- ₹15 crore
- Run by
- Dopesh Raja Mulakala
- Shareholders
- 426 people
- Listed since
- 2017
A very small company by stock-market value — prices can swing hard and trading can be thin.
02Is it growing?
Sales have shrunk 29% a year for 5 years.
Profit grew even faster, at −25% a year — the business is keeping more of each rupee it brings in.
Point at a bar for exact figures · amounts in ₹ crore
03Does it make money?
Out of every ₹100 it sells, it keeps ₹6.0 as profit.
Here is where the money from Vanta Bioscience's sales went in FY26, the latest full year it has reported.
₹30
₹43
₹21
- ₹30Costs of running the businessstaff, rent, marketing, power and everything else
- ₹43Interest on its loansthe cost of borrowed money
- ₹21Wear and tearmachines, stores and buildings losing value over time
- ₹6.0Profit it keepswhat is left for the company's owners
It also received a tax credit of ₹0.1 crore that year, which is why tax is missing from the bar.
On the money its owners have put in
It earns ₹1 a year on every ₹100 its owners have invested.
Bank FD ~₹6–7
₹1
₹-10₹0₹10₹20₹30₹40
That figure is called return on equity (ROE). Under ₹12 is a thin return for the risk of owning shares. For comparison, a bank fixed deposit pays roughly ₹6–7.
04Is the price high or low?
You pay ₹136 for every ₹1 of profit it makes in a year.
This is the P/E ratio: share price divided by a year's profit per share. A P/E of 136 means buyers are paying for about 136 years of today's profit up front.
The share price over the past year
It is 21% below its highest price of the past year and 39% above its lowest.
05Who owns it?
Its founders and parent group own 73 of every 100 shares — they control the company.
If the company were split into 100 equal shares, this is who would hold them. 426 people and institutions hold its shares.
As filed for the quarter ending 31 Mar 2026. Arrows show the change since the quarter before, in percentage points.
06What is going well, and what to watch
The figures raise more questions than they answer.
Picked out of the numbers above by fixed rules — the same rules for every company — so nothing here is somebody's opinion.
Going well
Nothing stands out in its favour in the figures we have.
Worth watching
- Sales have been shrinking — 29% a year.
- Owes ₹1.8 of debt for every ₹1 its owners have in the business.
- The share price is 136 times a year's profit, so it leans heavily on growth continuing.
- Thinly traded — only about ₹1 lakh of shares change hands a day, so buying or selling can move the price.
07What happened lately?
Its latest quarter.
Jan–Mar 2026 is the most recent quarter it has reported. Each figure is compared with the same three months a year earlier, because many businesses sell more in some seasons than others.
Sales
₹1.5 Cr
Profit
₹1.9 Cr
No notable developments in the last few weeks.
Advanced view
Every number, every table, the full chart.
Ten years of statements, quarterly results, peers side by side, technical indicators, analyst estimates, bulk deals and filings.
Ask DoXy
Still have a question about Vanta Bioscience?
This page describes Vanta Bioscience using its reported figures and exchange data. It is for information only and is not investment advice or a recommendation to buy, sell or hold. DocStoX is not a SEBI-registered investment adviser or research analyst.
Vanta Bioscience Ltd (VANTABIO): company summary
The company's annual revenue fell 7.1% to ₹2 crore, but the latest quarter revenue rose 357.6% to ₹2 crore compared to the same quarter a year earlier.
Vanta Bioscience Ltd (VANTABIO) is a micro-cap Healthcare company valued at ₹15 crore operating in Healthcare Technology on the NSE and BSE.
- Recent price move
- Vanta Bioscience Ltd last traded at ₹20.4, unchanged on the day.
- Recent developments
- On 2026-03-31, the company reported a net profit of ₹2 crore for the latest quarter, marking a swing from a net loss of ₹1 crore in the same quarter a year earlier. The company also reported a net profit of ₹0 crore for the fiscal year ending 2026-03-31, compared to a net loss of ₹5 crore in the previous fiscal year.
- Financial performance
- The company's annual revenue fell 7.1% to ₹2 crore, but the latest quarter revenue rose 357.6% to ₹2 crore compared to the same quarter a year earlier. Annual net profit swung from a net loss of ₹5 crore to a profit of ₹0 crore, while the latest quarter net profit swung from a net loss of ₹1 crore to a profit of ₹2 crore. The net profit margin improved 249.1 percentage points to 6.0%, but return on equity and return on capital employed remain low at 0.5% and 1.3% respectively.
- Valuation multiples
- The stock trades at 136.0 times earnings, a premium to the Healthcare median of 32.0, 0.69 times book value.
- Things to watch
- The company has a high debt to equity ratio of 1.80. The stock is 21.1% below its 52-week high. The company's revenue has declined at a compound annual growth rate of -28.6% over the past five years.
- Where it stands
- The company's latest quarter revenue rose 357.6% to ₹2 crore, while annual revenue fell 7.1% to ₹2 crore. The latest quarter net profit swung from a net loss of ₹1 crore to a profit of ₹2 crore, but the company's debt to equity ratio remains high at 1.80. The stock is 21.1% below its 52-week high.
Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
More Healthcare stocks · Healthcare Technology
Explore Vanta Bioscience Ltd’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Vanta Bioscience Ltd peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
Sun Pharmaceutical Industries LimitedDivi's Laboratories LimitedTorrent Pharmaceuticals LimitedLaurus Labs LimitedZydus Lifesciences LimitedApollo Hospitals Enterprise LimitedCipla LimitedDr. Reddy's Laboratories LimitedAurobindo Pharma LimitedMankind Pharma LimitedLupin LimitedManipal Health Enterprises Limited
Compare Vanta Bioscience Ltd with peers
Vanta Bioscience Ltd vs Sun Pharmaceutical Industries LimitedVanta Bioscience Ltd vs Divi's Laboratories LimitedVanta Bioscience Ltd vs Torrent Pharmaceuticals LimitedVanta Bioscience Ltd vs Laurus Labs LimitedVanta Bioscience Ltd vs Zydus Lifesciences LimitedVanta Bioscience Ltd vs Apollo Hospitals Enterprise Limited
Related tools & concepts
Value Vanta Bioscience Ltd with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing